Kolexia
Pigneux Arnaud Hématologie
Pigneux Arnaud
Hématologie
Hôpital Haut-lévêque
Pessac, France
353 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Maladie résiduelle Syndromes myélodysplasiques Leucémie-lymphome lymphoblastique à précurseurs B et T Tumeurs hématologiques Maladie du greffon contre l'hôte Récidive tumorale locale

Collaborateurs

Voir plus
Recher Christian
Recher Christian
Hôpital Purpan, Toulouse, France
Dumas Pierre-Yves
Dumas Pierre-Yves
Hôpital Haut-lévêque, Pessac, France
Vey Norbert
Vey Norbert
Centre Paoli-Calmettes, Marseille, France
Raffoux Emmanuel
Raffoux Emmanuel
Hôpital Saint-Louis, Paris, France

Industries

Voir plus
Abbvie
47 collaboration(s)
Dernière en 2023
Servier
20 collaboration(s)
Dernière en 2023
Astellas
12 collaboration(s)
Dernière en 2023
Edimark
12 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation: A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Essai Clinique (Astellas)   21 mars 2024
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy.
Cancer medicine   26 février 2024
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML: Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy
Essai Clinique (Syros Pharmaceuticals)   21 février 2024
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation: A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation
Essai Clinique (Forma Therapeutics, Inc.)   18 février 2024
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation: A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation
Essai Clinique (Celgene)   08 février 2024
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
Annals of hematology   26 janvier 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
Clinical lymphoma, myeloma & leukemia   18 janvier 2024
Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia.
EJHaem   10 janvier 2024
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
Leukemia research   09 janvier 2024
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Phase 1, Open-label, Dose Finding Study of CC-95251 Alone and in Combination With Antineoplastic Agents in Subjects With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Essai Clinique (BMS)   02 janvier 2024